The Cost-Effectiveness of Efgartigimod Alfa (Vyvgart) in the Treatment of Myasthenia Gravis: An Insight

By Danélia Botes

December 18, 2023

 The Purpose and Pricing of Efgartigimod Alfa

Efgartigimod Alfa, a drug designed to ameliorate symptoms of Generalised Myasthenia Gravis (gMG), has been reimbursed since April 2023 in Japan. The drug is priced at JPY 421,455 for Vyvgart® for intravenous infusion 400 mg as of September 2023. Center for Outcomes Research and Economic Evaluation for Health (C2H) calculate the price using a model for the Efgartigimod Alfa Cost-effectiveness. They then add a 5% usefulness premium and a 10% market premium. 

The Scope of the Efgartigimod Alfa Cost-effectiveness

The cost-effectiveness evaluation of Efgartigimod alfa targets two populations: acetylcholine receptor antibody-positive and antibody-negative patients. The comparators were prednisolone ± immunosuppressive drug ± acetylcholinesterase inhibitor.

Evaluation of Additional Benefits

The manufacturer did not conduct a systematic review in the base case analysis but evaluated the additional benefits of Efgartigimod alfa for patients with gMG as a whole. The academic group decided to evaluate based on scope. They assessed additional benefits for each population using the ADAPT trial. 

Results of the Cost-effectiveness Analysis

The manufacturer conducted a cost-utility analysis using a Markov model, which had states of Efgartigimod alfa or the comparator as first-line treatments, intravenous immunoglobulin or plasma exchange as second-line treatments, eculizumab as third-line treatment (only for population [a]), and the best supportive care.

The Expert Committee of Cost-Effectiveness Evaluation accepted the following:

Reference url

Recent Posts

Cost and clinical impact of MIS-C

Understanding the Cost and Clinical Impact of Multisystem Inflammatory Syndrome in Children (MIS-C)

🔍 Discovering the Economic Impact of Multisystem Inflammatory Syndrome in Children (MIS-C) 🏥💰

Understanding the cost and clinical impact of MIS-C during COVID-19 is crucial for healthcare providers and policymakers. Learn about treatment costs, patient outcomes, and key statistics related with MIS-C.

🌟#Healthcare #MIS-C #COVID19 #Pediatrics #HealthEconomics #MedicalResearch #HealthcareResearch #MedicalEconomics 📊

Let’s navigate the intersection of healthcare and economics together! 💼 #HealthcareInsights #EconomicAnalysis 🧠


Striking the Balance: Optimising Hepatitis B Treatment Strategies in The Gambia

Hepatitis B continues to pose a significant public health challenge, but the World Health Organization continues to work towards achieving their ambition of eliminating HBV as a public health problem by 2030.

One strategy is the Treat All approach, which sounds promising – however, in low-resource settings implementing promising strategies becomes more complex. This study explores striking the balance between promising strategies and getting people the treatment they need.

Learn more about innovative HBV treatment approaches and their impact on global health. Stay informed and join the conversation! 💡🔬 #HealthcareInnovation #HBVResearch

cost effectiveness multiple sclerosis

Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Exploring the Cost-Utility of MS Treatments: A Comprehensive Review 🧠💼 Dive into the latest findings on the cost-effectiveness of Disease-Modifying Drugs for Multiple Sclerosis. Discover key insights and recommendations for optimizing treatment strategies. #MSresearch #HealthcareEconomics #Neurology #HealthTech 📊🔬

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.